Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giorgia Nardo

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
Biochimie|January 17, 2012
Metabolic effects of anti-angiogenic therapy in tumorsElisabetta Zulato, Matteo Curtarello, Giorgia Nardo, et al.
Molecular Aspects of Medicine|February 20, 2007
RNA interference: implications for cancer treatmentMassimo Masiero, Giorgia Nardo, Stefano Indraccolo, et al.
Diagnostics (Basel, Switzerland)|August 27, 2021
Implementation of Next Generation Sequencing-Based Liquid Biopsy for Clinical Molecular Diagnostics in Non-Small Cell Lung Cancer (NSCLC) PatientsElisabetta Zulato, Valeria Tosello, Giorgia Nardo, et al.
Molecular Cancer Therapeutics|July 19, 2011
Long pentraxin-3 inhibits FGF8b-dependent angiogenesis and growth of steroid hormone-regulated tumorsDaria Leali, Patrizia Alessi, Daniela Coltrini, et al.
Frontiers in Oncology|June 20, 2018
Involvement of NADPH Oxidase 1 in Liver Kinase B1-Mediated Effects on Tumor Angiogenesis and GrowthElisabetta Zulato, Francesco Ciccarese, Giorgia Nardo, et al.
International Journal of Molecular Sciences|December 22, 2019
Detection of Loss of Heterozygosity in cfDNA of Advanced <i>EGFR</i>- or <i>KRAS</i>-Mutated Non-Small-Cell Lung Cancer PatientsElisa Boldrin, Giorgia Nardo, Elisabetta Zulato, et al.
Frontiers in Oncology|September 25, 2020
<i>In situ</i> Metabolic Profiling of Ovarian Cancer Tumor Xenografts: A Digital Pathology ApproachIlaria Piga, Martina Verza, Francesca Montenegro, et al.
Frontiers in Oncology|February 1, 2021
Detection of Low-Frequency <i>KRAS</i> Mutations in cfDNA From <i>EGFR</i>-Mutated NSCLC Patients After First-Line EGFR Tyrosine Kinase InhibitorsGiorgia Nardo, Jessica Carlet, Ludovica Marra, et al.
Anticancer Research|December 29, 2010
Prognostic and predictive implications of EGFR mutations, EGFR copy number and KRAS mutations in advanced stage lung adenocarcinomaLaura Bonanno, Marco Schiavon, Giorgia Nardo, et al.
Cellular Oncology (Dordrecht, Netherlands)|August 20, 2015
Manipulation of tumor metabolism for therapeutic approaches: ovarian cancer-derived cell lines as a model systemKristina Goetze, Christian G Fabian, Andrea Siebers, et al.
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
Biochimie|January 17, 2012
Metabolic effects of anti-angiogenic therapy in tumorsElisabetta Zulato, Matteo Curtarello, Giorgia Nardo, et al.
Molecular Aspects of Medicine|February 20, 2007
RNA interference: implications for cancer treatmentMassimo Masiero, Giorgia Nardo, Stefano Indraccolo, et al.
Diagnostics (Basel, Switzerland)|August 27, 2021
Implementation of Next Generation Sequencing-Based Liquid Biopsy for Clinical Molecular Diagnostics in Non-Small Cell Lung Cancer (NSCLC) PatientsElisabetta Zulato, Valeria Tosello, Giorgia Nardo, et al.
Molecular Cancer Therapeutics|July 19, 2011
Long pentraxin-3 inhibits FGF8b-dependent angiogenesis and growth of steroid hormone-regulated tumorsDaria Leali, Patrizia Alessi, Daniela Coltrini, et al.
Frontiers in Oncology|June 20, 2018
Involvement of NADPH Oxidase 1 in Liver Kinase B1-Mediated Effects on Tumor Angiogenesis and GrowthElisabetta Zulato, Francesco Ciccarese, Giorgia Nardo, et al.
International Journal of Molecular Sciences|December 22, 2019
Detection of Loss of Heterozygosity in cfDNA of Advanced <i>EGFR</i>- or <i>KRAS</i>-Mutated Non-Small-Cell Lung Cancer PatientsElisa Boldrin, Giorgia Nardo, Elisabetta Zulato, et al.
Frontiers in Oncology|September 25, 2020
<i>In situ</i> Metabolic Profiling of Ovarian Cancer Tumor Xenografts: A Digital Pathology ApproachIlaria Piga, Martina Verza, Francesca Montenegro, et al.
Frontiers in Oncology|February 1, 2021
Detection of Low-Frequency <i>KRAS</i> Mutations in cfDNA From <i>EGFR</i>-Mutated NSCLC Patients After First-Line EGFR Tyrosine Kinase InhibitorsGiorgia Nardo, Jessica Carlet, Ludovica Marra, et al.
Anticancer Research|December 29, 2010
Prognostic and predictive implications of EGFR mutations, EGFR copy number and KRAS mutations in advanced stage lung adenocarcinomaLaura Bonanno, Marco Schiavon, Giorgia Nardo, et al.
Cellular Oncology (Dordrecht, Netherlands)|August 20, 2015
Manipulation of tumor metabolism for therapeutic approaches: ovarian cancer-derived cell lines as a model systemKristina Goetze, Christian G Fabian, Andrea Siebers, et al.
Pageof 3